{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:11:51Z","timestamp":1790745111141,"version":"4.1.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T00:00:00Z","timestamp":1505952000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T00:00:00Z","timestamp":1505952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["U01 HG007269"],"award-info":[{"award-number":["U01 HG007269"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1111\/bjd.15498","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T15:53:26Z","timestamp":1490630006000},"page":"1102-1112","source":"Crossref","is-referenced-by-count":23,"title":["Is universal <i>HLA-B*15:02<\/i>\n screening a cost-effective option in an ethnically diverse population? A case study of Malaysia"],"prefix":"10.1093","volume":"177","author":[{"given":"H.Y.","family":"Chong","sequence":"first","affiliation":[{"name":"School of Pharmacy; Monash University Malaysia; Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Pharmacology; Faculty of Medicine; University of Malaya; Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L.","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Dermatology; University Malaya Medical Center; Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.B.C.","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Pharmacy; Monash University Malaysia; Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.H.","family":"Shabaruddin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Faculty of Medicine; University of Malaya; Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dahlui","sequence":"additional","affiliation":[{"name":"Department of Social and Preventive Medicine; Faculty of Medicine; University of Malaya; Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.D.","family":"Apalasamy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology; Faculty of Medicine; University of Malaya; Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Snyder","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Services Research; Geisinger Health System; Danville PA U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Williams","sequence":"additional","affiliation":[{"name":"Genomic Medicine Institute; Geisinger Health System; Danville PA U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Services Research; Geisinger Health System; Danville PA U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.H.","family":"Cavallari","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research; University of Florida; Gainesville FL U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Chaiyakunapruk","sequence":"additional","affiliation":[{"name":"School of Pharmacy; Monash University Malaysia; Malaysia"},{"name":"Asian Centre for Evidence Synthesis in Population, Implementation and Clinical Outcomes (PICO); Health and Well-being Cluster, Global Asia in the 21st Century (GA21) Platform; Monash University Malaysia; Malaysia"},{"name":"Center of Pharmaceutical Outcomes Research (CPOR); Department of Pharmacy Practice; Faculty of Pharmaceutical Sciences; Naresuan University; Phitsanulok Thailand"},{"name":"School of Pharmacy; University of Wisconsin; Madison WI U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,9,21]]},"reference":[{"key":"10.1111\/bjd.15498-BIB0001|bjd15498-cit-0001","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/jhg.2013.37","article-title":"Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury","volume":"58","author":"Kaniwa","year":"2013","journal-title":"J Hum Genet"},{"key":"10.1111\/bjd.15498-BIB0002|bjd15498-cit-0002","first-page":"1","article-title":"Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Sarawak: a four years\u2019 review","volume":"4","author":"Yap","year":"2008","journal-title":"Egypt Dermatol Online J"},{"key":"10.1111\/bjd.15498-BIB0003|bjd15498-cit-0003","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.15498-BIB0004|bjd15498-cit-0004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphan J Rare Dis"},{"key":"10.1111\/bjd.15498-BIB0005|bjd15498-cit-0005","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/CCM.0b013e31821201ed","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review","volume":"39","author":"Gerull","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1111\/bjd.15498-BIB0006|bjd15498-cit-0006","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1398-9995.2006.01295.x","article-title":"Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series","volume":"62","author":"Yip","year":"2007","journal-title":"Allergy"},{"key":"10.1111\/bjd.15498-BIB0007|bjd15498-cit-0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.15498-BIB0008|bjd15498-cit-0008","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.15498-BIB0009|bjd15498-cit-0009","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.dsi.2013.09.007","article-title":"Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in Southeast Asia","volume":"31","author":"Lee","year":"2013","journal-title":"Dermatol Sin"},{"key":"10.1111\/bjd.15498-BIB0010|bjd15498-cit-0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13023-017-0566-8","article-title":"Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940-2015","volume":"12","author":"Sweileh","year":"2017","journal-title":"Orphan J Rare Dis"},{"key":"10.1111\/bjd.15498-BIB0011|bjd15498-cit-0011","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1111\/bjd.15498-BIB0012|bjd15498-cit-0012","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5415\/apallergy.2013.3.4.215","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: an Asia-Pacific perspective","volume":"3","author":"Thong","year":"2013","journal-title":"Asia Pacific Allergy"},{"key":"10.1111\/bjd.15498-BIB0013|bjd15498-cit-0013","unstructured":"Cox W Asians: America's fastest growing minority http:\/\/www.newgeography.com\/content\/004825-asians-americas-fastest-growing-minority"},{"key":"10.1111\/bjd.15498-BIB0014|bjd15498-cit-0014","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1111\/bjd.15498-BIB0015|bjd15498-cit-0015","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2013.103","article-title":"Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing","volume":"94","author":"Leckband","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/bjd.15498-BIB0016|bjd15498-cit-0016","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/epi.12325","article-title":"Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand","volume":"54","author":"Rattanavipapong","year":"2013","journal-title":"Epilepsia"},{"key":"10.1111\/bjd.15498-BIB0017|bjd15498-cit-0017","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/epi.12937","article-title":"Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy","volume":"56","author":"Plumpton","year":"2015","journal-title":"Epilepsia"},{"key":"10.1111\/bjd.15498-BIB0018|bjd15498-cit-0018","volume-title":"Pharmacoeconomic Guideline for Malaysia","author":"Ministry of Health Malaysia","year":"2012"},{"key":"10.1111\/bjd.15498-BIB0019|bjd15498-cit-0019","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.yebeh.2012.12.034","article-title":"Impact of epilepsy on employment in Malaysia","volume":"27","author":"Lim","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1111\/bjd.15498-BIB0020|bjd15498-cit-0020","volume-title":"Consensus Guidelines on the Management of Epilepsy","author":"Epilepsy Council","year":"2010"},{"key":"10.1111\/bjd.15498-BIB0021|bjd15498-cit-0021","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1212\/WNL.0b013e31823b478c","article-title":"Severe cutaneous adverse reactions to antiepileptic drugs in Asians","volume":"77","author":"Yang","year":"2011","journal-title":"Neurology"},{"key":"10.1111\/bjd.15498-BIB0022|bjd15498-cit-0022","first-page":"CD001030","article-title":"Carbamazepine versus valproate monotherapy for epilepsy","volume":"3","author":"Marson","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/bjd.15498-BIB0023|bjd15498-cit-0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-8-34","article-title":"Multiple treatment comparisons in epilepsy monotherapy trials","volume":"8","author":"Tudur Smith","year":"2007","journal-title":"Trials"},{"key":"10.1111\/bjd.15498-BIB0024|bjd15498-cit-0024","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta11370","article-title":"A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial","volume":"11","author":"Marson","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1111\/bjd.15498-BIB0025|bjd15498-cit-0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1528-1157.1980.tb04088.x","article-title":"Mortality in patients with epilepsy","volume":"21","author":"Hauser","year":"1980","journal-title":"Epilepsia"},{"key":"10.1111\/bjd.15498-BIB0026|bjd15498-cit-0026","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1528-1157.1997.tb01194.x","article-title":"Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy","volume":"38","author":"Nilsson","year":"1997","journal-title":"Epilepsia"},{"key":"10.1111\/bjd.15498-BIB0027|bjd15498-cit-0027","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/ana.70","article-title":"Mortality in epilepsy in the first 11 to 14\u00a0years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort","volume":"49","author":"Lhatoo","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1111\/bjd.15498-BIB0028|bjd15498-cit-0028","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1528-1157.2000.tb00124.x","article-title":"Mortality risk in an adult cohort with a newly diagnosed unprovoked epileptic seizure: a population-based study","volume":"41","author":"Lindsten","year":"2000","journal-title":"Epilepsia"},{"key":"10.1111\/bjd.15498-BIB0029|bjd15498-cit-0029","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp.66.5.636","article-title":"Mortality in patients with epilepsy: 40\u00a0years of follow up in a Dutch cohort study","volume":"66","author":"Shackleton","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/bjd.15498-BIB0030|bjd15498-cit-0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(06)70448-3","article-title":"Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study","volume":"5","author":"Mohanraj","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1111\/bjd.15498-BIB0031|bjd15498-cit-0031","first-page":"CD001902","article-title":"Early versus late antiepileptic drug withdrawal for people with epilepsy in remission","volume":"2","author":"Strozzi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/bjd.15498-BIB0032|bjd15498-cit-0032","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00023210-200418040-00001","article-title":"Should antiepileptic drugs be withdrawn in seizure-free patients?","volume":"18","author":"Specchio","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1111\/bjd.15498-BIB0033|bjd15498-cit-0033","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-4632.2010.04745.x","article-title":"Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population","volume":"50","author":"Chang","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1111\/bjd.15498-BIB0034|bjd15498-cit-0034","unstructured":"Gonzalez-Galarza F Christmas S Middleton D Jones A Allele frequency net: a database and online repository for immune gene frequencies in worldwide population http:\/\/www.allelefrequencies.net"},{"key":"10.1111\/bjd.15498-BIB0035|bjd15498-cit-0035","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/epi.12802","article-title":"HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis","volume":"55","author":"Khor","year":"2014","journal-title":"Epilepsia"},{"key":"10.1111\/bjd.15498-BIB0036|bjd15498-cit-0036","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0198-8859(01)00247-6","article-title":"Analysis of the distribution of HLA-B alleles in populations from five continents","volume":"62","author":"Williams","year":"2001","journal-title":"Hum Immunol"},{"key":"10.1111\/bjd.15498-BIB0037|bjd15498-cit-0037","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1212\/WNL.0b013e31826aac73","article-title":"Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore","volume":"79","author":"Dong","year":"2012","journal-title":"Neurology"},{"key":"10.1111\/bjd.15498-BIB0038|bjd15498-cit-0038","volume-title":"Consumer Price Index Malaysia, August 2016","author":"Department of Statistics Malaysia","year":"2016"},{"key":"10.1111\/bjd.15498-BIB0039|bjd15498-cit-0039","unstructured":"Central Bank of Malaysia Kuala Lumpur USD\/MYR reference rate http:\/\/www.bnm.gov.my\/index.php?ch=statistic&pg=kualalumpurusdmyrreferencerate"},{"key":"10.1111\/bjd.15498-BIB0040|bjd15498-cit-0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2340\/00015555-2295","article-title":"Long-term sequelae of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"96","author":"Yang","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.15498-BIB0041|bjd15498-cit-0041","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11096-007-9185-0","article-title":"Cost of illness of tuberculosis in Penang","volume":"30","author":"Elamin","year":"2008","journal-title":"Malaysia. Pharm World Sci"},{"key":"10.1111\/bjd.15498-BIB0042|bjd15498-cit-0042","volume-title":"National Health and Morbidity Survey 2011: Fact Sheet","author":"Ministry of Health Malaysia","year":"2011"},{"key":"10.1111\/bjd.15498-BIB0043|bjd15498-cit-0043","volume-title":"Salaries and Wages Survey Reports","author":"Department of Statistics Malaysia","year":"2015"},{"key":"10.1111\/bjd.15498-BIB0044|bjd15498-cit-0044","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol - a new facility for the measurement of health-related quality of life","volume":"16","author":"The EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1111\/bjd.15498-BIB0045|bjd15498-cit-0045","doi-asserted-by":"crossref","first-page":"e94294","DOI":"10.1371\/journal.pone.0094294","article-title":"Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS\/TEN in Thai population","volume":"9","author":"Saokaew","year":"2014","journal-title":"PLOS ONE"},{"issue":"Suppl. 1","key":"10.1111\/bjd.15498-BIB0046|bjd15498-cit-0046","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.jval.2011.11.024","article-title":"Estimating an EQ-5D value set for Malaysia using time trade-off and visual analogue scale methods","volume":"15","author":"Yusof","year":"2012","journal-title":"Value Health"},{"key":"10.1111\/bjd.15498-BIB0047|bjd15498-cit-0047","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/MLR.0b013e318234a04a","article-title":"Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods","volume":"50","author":"Ara","year":"2012","journal-title":"Med Care"},{"key":"10.1111\/bjd.15498-BIB0048|bjd15498-cit-0048","volume-title":"Monthly Statistical Bulletin Malaysia, May 2016","author":"Department of Statistics Malaysia","year":"2016"},{"key":"10.1111\/bjd.15498-BIB0049|bjd15498-cit-0049","unstructured":"Malaysian Health Technology Assessment Section Establishing a cost-effectiveness threshold value for health technologies http:\/\/www.moh.gov.my\/index.php\/pages\/view\/1561"},{"key":"10.1111\/bjd.15498-BIB0050|bjd15498-cit-0050","unstructured":"World Health Organization (WHO) Choosing interventions that are cost-effective (WHO-CHOICE) http:\/\/www.who.int\/choice\/en\/"},{"key":"10.1111\/bjd.15498-BIB0051|bjd15498-cit-0051","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00019053-200321010-00003","article-title":"Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies","volume":"21","author":"Zethraeus","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/bjd.15498-BIB0052|bjd15498-cit-0052","volume-title":"Fees (Medical) (Cost of Services) Order 2014 (P.U. (A) 363)","author":"Attorney General's Chambers of Malaysia","year":"2014"},{"key":"10.1111\/bjd.15498-BIB0053|bjd15498-cit-0053","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40273-016-0397-9","article-title":"A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions","volume":"34","author":"Plumpton","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/bjd.15498-BIB0054|bjd15498-cit-0054","volume-title":"Modern Immigration Wave Brings 59 Million to US, Driving Population Growth and Change Through 2065: View of Immigration's Impact on US Society Mixed","author":"Pew Research Center","year":"2015"},{"key":"10.1111\/bjd.15498-BIB0055|bjd15498-cit-0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.burns.2015.03.012","article-title":"Complications of Stevens-Johnson syndrome beyond the eye and skin","volume":"42","author":"Saeed","year":"2016","journal-title":"Burns"},{"key":"10.1111\/bjd.15498-BIB0056|bjd15498-cit-0056","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jtos.2016.02.001","article-title":"Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome\/toxic epidermal necrolysis - a comprehensive review and guide to therapy. II. Ophthalmic disease","volume":"14","author":"Kohanim","year":"2016","journal-title":"Ocul Surf"},{"key":"10.1111\/bjd.15498-BIB0057|bjd15498-cit-0057","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/ICU.0000000000000312","article-title":"Ocular manifestations of Stevens-Johnson syndrome and their management","volume":"27","author":"Saeed","year":"2016","journal-title":"Curr Opin Ophthalmol"},{"issue":"Suppl. 1","key":"10.1111\/bjd.15498-BIB0058|bjd15498-cit-0058","first-page":"27","article-title":"Pharmacogenomics screening of HLA-B*1502 in epilepsy patients: how we do it in the UKM Medical Center, Malaysia","volume":"18","author":"Then","year":"2013","journal-title":"Neurol Asia"},{"key":"10.1111\/bjd.15498-BIB0059|bjd15498-cit-0059","doi-asserted-by":"crossref","first-page":"734","DOI":"10.4103\/0378-6323.102367","article-title":"An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia","volume":"78","author":"Choon","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.15498","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.15498\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:26:30Z","timestamp":1676384790000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/177\/4\/1102\/6674045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,21]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.15498","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9,21]]}}}